Fig. 1

Therapeutic efficacy of Realgar in the murine MDS model (NUP98-HOXD13). (A) Complete blood count (CBC) analysis of peripheral blood from wild-type, NHD13, and Realgar-treated mice (n = 5). WBC, white blood cells; RBC, red blood cells; HB, hemoglobin; PLT, platelets. (B) Histopathological examination of liver, spleen, heart, and kidney tissues from each group. Sections were stained with H&E. Scale bar, 200 μm. (C) Body weight changes in WT, murine MDS model, and Realgar-treated mice during the treatment period. Data are presented as mean ± SD (n = 5). (D) Quantification of colony formation in cultures of nucleated BM or spleen cells isolated from WT, NHD13, or Realgar-treated groups, cultured in BFU-E medium for 12 days or CFU-E medium for 2 days. Data are presented as mean ± SEM (n = 3). (E) (Left) Flow cytometric analysis of erythroblasts in BM from the three groups. Erythroblasts were classified into four subpopulations based on surface staining for CD71 and Ter-119: Ter-119^medCD71^high proerythroblasts (R1), Ter-119^highCD71^high basophilic erythroblasts (R2), Ter-119^highCD71^med late basophilic and polychromatophilic erythroblasts (R3), and Ter- 119^highCD71.^low orthochromatophilic erythroblasts (R4). (F) (Right) Quantification of the percentages of R1–R4 populations shown in the left panel. Data are presented as mean ± SEM (n = 5). (*, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant)